Our results confirm the potential of CRABP1 as a biomarker of DTC, based in a large number of DTC (n = 89) encompassing several subtypes – FTC, FVPTC and PTC, and controlled by a pool of normal thyroid tissues and of benign tumours – FTA. This evidence concerns the gene CRABP1 and benign neoplasm.